系统性红斑狼疮中抗髓鞘和神经元抗原抗体与神经炎症的关联
该研究在瑞士SLE队列中筛查174例SLE患者的12种抗神经系统抗原抗体,发现13.2%患者抗体阳性,以抗MOG抗体最常见(8%);抗NS抗体阳性患者NPSLE频率显著高于抗体阴性者(56.5% vs 13.9%,P<0.0001),部分阳性患者呈现与抗体相关的独特神经综合征。
要点
- SLE患者中抗NS抗体阳性率13.2%,抗MOG抗体最常见(8%)。
- 抗NS抗体阳性者NPSLE频率显著高于阴性者(56.5% vs 13.9%,P<0.0001)。
- 部分抗NS抗体阳性患者呈现与抗体相关的独特神经综合征。
核心结论
- 抗NS抗体(最普遍为抗MOG抗体)与NPSLE显著相关,部分患者表现为与抗体相关的独特神经综合征。
研究设计与样本
- 回顾性初步研究,纳入瑞士SLE队列研究中的174例SLE患者进行横断面分析,其中102例进行纵向研究。
- 采用经验证的细胞学方法筛查针对12种NS抗原的抗体,并与临床和诊断发现进行关联分析。
主要发现
- 174例患者中23例(13.2%)携带抗NS抗体:抗MOG(n=14)、抗NF186(n=6)、抗GAD65(n=2)、抗AQP4和抗GlyR(n=1)。
- 抗MOG抗体在队列中最常见(8%)。
- 23例抗NS抗体阳性患者中13例出现NS受累临床症状,其中8例类似与抗体相关的综合征;9例携带抗体但无神经系统症状,1例失访。
- 抗NS抗体阳性患者NPSLE频率为56.5%(13/23;MOG 6/14,42.9%;NF186 5/6,83.3%;GAD65 2/2,100%;AQP4/GlyR 0/1,0%),显著高于抗体阴性队列的13.9%(21/151)(卡方检验,P<0.0001)。
关键数值与推荐
- 抗NS抗体阳性患者NPSLE频率56.5% vs 抗体阴性者13.9%,P<0.0001。
- 各抗体阳性亚组NPSLE频率:抗MOG 42.9%(6/14)、抗NF186 83.3%(5/6)、抗GAD65 100%(2/2)、抗AQP4/GlyR 0%(0/1)。
临床怎么用
- 在SLE患者中可考虑筛查抗NS抗体(尤其抗MOG抗体)以辅助识别NPSLE高风险患者。
- 抗NS抗体阳性且出现神经系统症状的患者可能表现为与抗体相关的独特神经综合征,需针对性评估。
局限性
- 本研究为回顾性初步研究,样本量有限,需在大型独立队列中随访验证。
- 抗NS抗体能否作为NPSLE的诊断和预后生物标志物尚待进一步研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine frequency and syndrome specificity of novel and known nervous system (NS)-directed antibodies in a large, unbiased cohort of SLE patients in the Swiss SLE Cohort Study. METHODS: This retrospective pilot study included 174 patients in a cross-sectional and 102 in a longitudinal study. Antibodies against 12 NS antigens [myelin oligodendrocyte glycoprotein (MOG), neurofascin 186 (NF186), aquaporin-4 (AQP4), N-methyl-D-aspartate receptor (subunit NR1) (NMDAR-NR1), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (subunits 1 and 2) (AMPAR1/2), gamma-aminobutyric acid B receptor (subunits B1 and B2) (GABABR1/2), glutamate decarboxylase 65 (GAD65), glycine receptor (GlyR), contactin-associated protein-like 2 (CASPR2), leucine-rich glioma-inactivated 1 (LGI1), metabotropic glutamate receptor 5 (mGluR5) and dipeptidyl-peptidase-like protein 6 (DPPX)] were screened with validated cell-based assays and correlated with clinical and diagnostic findings. RESULTS: Twenty-three of one hundred and seventy-four (13.2%) patients harboured antibodies against MOG (n = 14), NF186 (n = 6), GAD65 (n = 2), AQP4 and GlyR (n = 1). Anti-MOG antibodies were most frequently found in the cohort (8%). Thirteen of the anti-NS antibody-positive patients showed clinical symptoms of NS involvement, a subgroup of which (n = 8) resembled the syndrome associated with the antibody. Nine patients harboured antibodies without neurological symptoms and one patient was lost to follow-up. The frequency of NPSLE was significantly higher in the anti-NS antibody-positive patients (13/23, 56.5%: MOG 6/14, 42.9%; NF186 5/6, 83.3%; GAD65 2/2, 100%; AQP4/GlyR 0/1, 0%) compared with the antibody-negative cohort (21/151, 13.9%) (chi-square test, P < 0.0001). CONCLUSION: Anti-NS antibodies, most prevalently anti-MOG antibodies, are significantly associated with NPSLE and manifest with the distinct neurological syndrome associated with the antibody in a subgroup. Follow-up studies in large, independent cohorts will reveal whether these anti-NS antibodies could serve as a diagnostic and prognostic biomarker for NPSLE and enable tailored treatment decisions in this challenging and diverse patient cohort.
引用
- Pröbstel AK, Thanei M, Erni B, et al. Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus. Rheumatology (Oxford). 2019. PMID: 30265368. doi:10.1093/rheumatology/key282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。